Comparative Pharmacology
Head-to-head clinical analysis: GEMCITABINE versus OTREXUP PFS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GEMCITABINE versus OTREXUP PFS.
GEMCITABINE vs OTREXUP PFS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gemcitabine is a nucleoside analog (2',2'-difluorodeoxycytidine) that is phosphorylated intracellularly to active diphosphate (dFdCDP) and triphosphate (dFdCTP) metabolites. dFdCDP inhibits ribonucleotide reductase, reducing deoxynucleotide pools for DNA synthesis. dFdCTP competes with deoxycytidine triphosphate for incorporation into DNA, causing masked chain termination and inhibiting DNA polymerase and repair.
Methotrexate is a folate analog that inhibits dihydrofolate reductase, thereby blocking the synthesis of purines and pyrimidines, leading to inhibition of DNA synthesis and cell proliferation. It also has immunosuppressive and anti-inflammatory effects through modulation of adenosine pathways and cytokine release.
1000-1250 mg/m² intravenously over 30 minutes on days 1 and 8 of a 21-day cycle.
Methotrexate 7.5-15 mg subcutaneously once weekly. For rheumatoid arthritis, start at 7.5 mg weekly, titrate to 20-25 mg weekly as tolerated.
None Documented
None Documented
Clinical Note
moderateGemcitabine + Digoxin
"Gemcitabine may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateGemcitabine + Digitoxin
"Gemcitabine may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateGemcitabine + Deslanoside
"Gemcitabine may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateGemcitabine + Acetyldigitoxin
"Gemcitabine may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life for gemcitabine is 42-94 minutes (mean ~57 min) in plasma; for its metabolite dFdU, the half-life is 14-74 hours (mean ~40 h), which accumulates with repeated dosing and may contribute to prolonged systemic exposure.
5-8 hours (low-dose methotrexate); 8-15 hours (high-dose). Prolonged in renal impairment, third-space effusions, or concomitant NSAIDs.
Primarily renal: ~92-98% of the dose excreted in urine, with <10% as unchanged gemcitabine and the majority as the inactive metabolite 2',2'-difluorodeoxyuridine (dFdU). Fecal excretion is minimal (<1%).
Renal excretion (80-90% unchanged) via glomerular filtration and tubular secretion; biliary/fecal elimination accounts for <10%.
Category D/X
Category C
Antimetabolite
Antimetabolite